Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is actively expanding its traditional Chinese medicine (TCM) industry chain by constructing a medicinal herb base and initiating multiple new research and development (R&D) projects [3][4][5] - The company reported a revenue of 298 million yuan for Q1-Q3 2024, a year-on-year increase of 0.66%, while the net profit attributable to shareholders was 57.21 million yuan, a decrease of 12.22% year-on-year [3] - The company is increasing its R&D investment, with R&D expenses reaching 7.79 million yuan in Q1-Q3 2024, a growth of 33.02% year-on-year [4] Financial Summary - The total market capitalization of the company is 1.638 billion yuan, with a circulating market capitalization of 1.250 billion yuan [1] - The company's earnings per share (EPS) forecasts for 2024-2026 are adjusted to 0.73, 0.80, and 0.86 yuan per share, respectively, with corresponding price-to-earnings (P/E) ratios of 15.4, 13.9, and 13.0 times [3][6] - The company plans to invest 28 million yuan through its wholly-owned subsidiary to indirectly control a company that will facilitate the construction of a medicinal herb base [5]
梓橦宫：北交所信息更新：布局拓展中医药产业链建设药材基地，多个新研发项目启动